IDEXX Laboratories (IDXX)

As of 30 September 2026, short interest in IDXX is 1,940,639 shares, down 151,441 shares over the last month. Over the last 48 readings it ranged from 1,202,142 shares (29 November 2024) to 3,027,233 shares (15 May 2025). At the reported average volume of 496K shares a day that is 3.9 days to cover.

<iframe src="https://xoomar.com/embed/stocks/idxx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 9 October 2026, the short share of IDXX volume is 41.6%, down 17.8 points over the last five sessions. Over the last 30 readings it ranged from 19.7% (14 September 2026) to 70.7% (29 September 2026). The latest reading is in line with the 30-session average of 39.9%, on 156K shares reported.

As of 11 September 2026, the fails-to-deliver balance in IDXX is 2 shares, down 822 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (12 February 2026) to 60,495 shares (25 June 2026). The latest reading sits at the bottom of that range.

Insiders at IDXX reported 1 open-market sell worth $1.2M in the last 90 days and no open-market buys. Latest filing: Kingsley Lawrence D (Director) on 2026-09-04.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

8 Form 144 notices on file for IDXX worth $37.7M at the prices reported; 1 in the last 90 days worth $1.2M. Latest: LAWRENCE D KINGSLEY filed on 2026-09-04 to sell 2,203 shares ($1.2M) from 2026-09-04.

1 holder reports 5% or more of IDXX in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (5,976,472 shares), filed 2026-04-30 for an event on 2026-03-31.

7 of the 30 tracked managers held IDXX at their latest 13F, $316.8M in total at quarter-end prices. Point72 Asset Management is the largest at $138.4M (0.2% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 FY 2026 (quarter ended 2026-06-30) IDEXX Laboratories reported revenue of $1.22B, up 9.7% from the same quarter a year earlier, and net income of $338.4M (4.27 diluted EPS). In FY 2025 it generated $1.18B of operating cash flow and spent $1.22B on buybacks. As of 2026-06-30, cash was $196.9M against $299.9M of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.